ESC Premium Access

Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study

Congress Session

About the speaker

Professor Andrew Wang

Duke University Medical Center, Durham (United States of America)
0 follower

4 more presentations in this session

State of the Art in the treatment of hypertrophic cardiomyopathy

Speaker: Professor I. Olivotto (Florence, IT)

Thumbnail

Earlier surgical myectomy vs. waiting for a Class I indication is associated with improved long-term survival in symptomatic hypertrophic obstructive cardiomyopathy patients

Speaker: Doctor M. Desai (Cleveland, US)

Thumbnail

A novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)

Speaker: Doctor G. Norrish (London, GB)

Thumbnail

Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.

Speaker: Professor J. Veselka (Prague, CZ)

Thumbnail

Access the full session

Novel therapeutic targets in hypertrophic cardiomyopathy

Speakers: Professor A. Wang, Professor I. Olivotto, Doctor M. Desai, Doctor G. Norrish, Professor J. Veselka
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

Related content

Open Access

Imaging in diagnosing hypertrophic obstructive cardiomyopathy.

30 August 2021

Open Access

Hypertrophic cardiomyopathy epidemiology and natural history.

30 August 2021

ESC Premium Access

More facets of acute myocarditis.

27 August 2021

This platform is supported by

logo Novo Nordisk